ReviewCancer cell international2026
FcγR-driven chimeric receptor T cells in cancer therapy: a novel frontier in antibody-guided immunotherapy.
Review in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review article looks at a novel and flexible framework in adaptive cell treatment that enhances tumor targeting using Fc gamma receptor (FcγR)-based chimeric receptors. Though chimeric antigen receptor (CAR) T cell therapies have shown notable effectiveness in hematologic malignancies, their efficiency against solid tumors is limited by tumor heterogeneity, immunosuppressive tumor microenvironments (TMEs), and off-target toxicities. By replacing the conventional scFv domain with the extracellular domains of FcγRs—including CD16a, CD32a, or CD64a—FcγR-CR T cells provide a unique method allowing T cells to be steered by monoclonal antibodies (mAbs) targeting several tumor-associated antigens (TAAs). Emphasizing their advantages in flexibility, reversibility, and compatibility with present antibody therapy, the review clarifies the mechanisms of action, preclinical developments, and clinical promise of FcγR-CR T cells. Future directions include increasing specificity by means of affinity-engineered FcγRs and Fc-modified monoclonal antibodies, generating universal allogeneic FcγR-CR T cells for immediate use, using regulatable expression systems to improve safety, and combining these engineered cells with immune checkpoint inhibitors or metabolic modulators to overcome tumor microenvironment resistance. Overall, FcγR-CR T cells offer a hopeful next-generation immunotherapeutic approach able to handle the current CAR T cell constraints and change precision oncology, particularly for aggressive and treatment-resistant solid cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.